Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decernotinib (VX-509) Phase 2b in RA with Inadequate Response to Methotrexate
NCT01590459Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Apr 2012
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 2 trial of decernotinib in rheumatoid arthritis (RA), sponsored by Vertex Pharmaceuticals. Started Apr 2012; status: completed.
02
Drugs
decernotinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01590459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01590459.